INTRODUCTION
For many years, pneumonia has remained one of the most significant diseases for the population and health systems around the world. High mortality and disability rates, a particular vulnerability of children and elderly and old people, high financial costs of patients' treatment and elimination of severe consequences of the disease that have occurred -all these factors require close attention to finding the best strategy for pneumonia pharmacotherapy [1, 2] .
In Russia, pneumonia is also a serious public health problem. According to the data of Russian Federal State Statistics Service, in the Russian Federation in the period from 2006 to the present, the incidence for every 100 thousand people of the adult population varies from 344.0 to 404.0.
In these circumstances, according to a number of authoritative scientists [3] [4] [5] [6] [7] , the real incidence may be significantly higher. Currently, CAP is the most common type of infection. The highest morbidity rates are recorded among the elderly people and children aged 4-5 years [2, [8] [9] [10] [11] .
The result of the wrong treatment regime, late diagnosis of patients, incomplete elimination of the inflammatory process at discharge from hospital in patients with pneumonia is the transition from an acute form to chronic. In addition, uncontrolled therapy causes the emergence of antibiotic resistance. 30% of pneumococcal strains today are known to have resistance to penicillin; the number of strains insensitive to cephalosporin antibiotics is growing progressively [12] .
Such medical factors as diagnostic errors (approximately in 20% of cases), delays with diagnosis (on average for 3 days) and others, lead to the appearance of pharmacotherapy problems. With uncontrolled therapy,
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The experience of the developed countries of the world shows that in medical and pharmaceutical practice, overcoming the potential problems of pharmacotherapy is greatly facilitated by the application of the principles and techniques of specialized pharmaceutical care (PhC), focused primarily on optimizing medical and informational support of a doctor and a patient [16] [17] [18] [19] [20] [21] [22] .
Over the past 20 years, PhCstudies in patients with various diseases have been carried out by Dremova N.B., Ovod A.I., Korzhavikh E.A. [23] [24] [25] [26] , Spichak I.V., Glembotsky G.T., Zakharova O.V., Alexeev I.V., Varenykh G.V., Trubina L.V., Petrov A.G. and others [27] [28] [29] [30] [31] [32] [33] .
In pharmacy, only a few works are devoted to the improvement of drug supply for patients with pneumonia: by Z. Zakaryaeva [34] , Wolfram N.A. [35] .
No research has been carried out on the subject matter of PhC in relation to the situation in the Kabardino-Balkarian Republic. At the same time, as the study of profile literature shows, a regional approach to improving drug provision for patients with various nosological forms of diseases is increasingly used in modern pharmaceutical research, both in foreign [36] [37] [38] [39] and in domestic kinds of research [40] [41] [42] .
It is noted that in the conditions of modern Russia, due to its large extension, climatic-geographical, economic, socio-demographic differences between the constituent territories of the Russian Federation, the regional approach makes it possible to justify the problem and arrive at the most correct decisions in the sphere of drug provision.
The researchers emphasize the fact that the relevance of finding rational schemes for the treatment of pneumonia is due to the significant costs associated with not only drugs but also medical consumables. In addition, foreign scientists also include the cost of consulting a specialist, laboratory and diagnostic studies in the cost of treatment [1, 8, 21, 22, 35, 39] .
All of theabove-listed indicates the relevance of a comprehensive analysis of drug supply issues for the subsequent rationalization of costs, as well as the achievement of the highest efficiency of drug treatment.
THE AIM of the study is to justify and develop a regional model of pharmacotherapy drug provision for patients with CAP.
MATERIALS AND METHODS
The objects of the study were statistical data on the Russian Federation and the KBR for 2008-2018, statistical reports of health care organizations, lists of drugs (State Register of Medicinal Remedies, vital essential and necessary medicines, treatment standards, etc.); the results of sociological surveys of doctors (30 questionnaires; a set sample), pharmacy workers (41 questionnaires), patients with CAP (70 questionnaires); price lists of wholesale and retail pharmaceutical organizations within the territory of the KBR (the actual range of drugs).
The leading research methods were: systematic, resource and regional approaches; methods of historical, logical, scientometric (content analysis), marketing (assortment structure, price), pharmacoeconomic (cost of disease) and economic and statistical analysis (grouping, variation statistics), sociological (questionnaire survey, expert assessments). The results were processed using standard computer programs.
On the basis of the preliminary research, a working hypothesis of the study was formulated: considering the problem from the standpoint of the resource approach and the ideology of specialized pharmaceutical care will allow the most complete and reasonable improvement of drug supply to patients with CAP within the territory of the KBR.
In accordance with this hypothesis, the following tasks were to be solved:
1. to assess the status and development trends of regional resources -organizational, personnel, financial (population), and drugs -as external factors of PhC for patients with CAP; 2. to characterize the internal factors of CAP pharmacotherapy in the KBR -doctors' prescriptions (stationary stage of medical care), consumer demand (outpatient stage), the cost of pharmacotherapy (inpatient and outpatient stages); 3. to form a regional conceptual model of drug provision for patients with CAP. To ensure the theoretical unity of the study, the following terms and definitions were used:
-drug provision -an organizational system (a set of measures) to bring drugs from the manufacturer to the consumer (Shukil LV, 2018) ; − drug care -a type of professional health care, aimed at the provision, prescription and use of drugs (Fomina AV, 2006) The following indicators of socio-demographic resource, compared with the average for the Russian Federation, refer to the features of the KBR region:
− lower proportion of the average annual number of the employed in the total population of the KBR; − higher rate of population ageing; − lower standard of living (subsistence minimum and per capita income); − outstripping growth of the General morbidity. In addition, the increase in the incidence of CAP per 100 thousand population for the period of 2013-2017 has been identified: 1) in the RF -by 1.06 times (in 2018 -already by 1.3 times), 2) in accordance with the resource approach, the pharmaceutical, organizational, human and medicinal resources of the model region have been evaluated, as they are most dependent on the state of the drug supply system.
Due to the lack of official statistics of pharmaceutical organizations to assess the pharmaceutical organizational resource in the country, we have analyzed the composition and structure of the collection of licensing entities (licensees) doing pharmaceutical activities in the region It has been established that in 2018, there were 382 holders of 547 licenses for pharmaceutical activities in the KBR. By legal status, the majority of licensees -211 (55.2%) -were legal entities; the number of individuals was 171 (44.8%). The distribution of licensees according to the form of ownership is presented in Table 2 . The results, shown in Table 2 , indicate a clear predominance of private owners among pharmaceutical license holders -87.17%; these are mainly self-employed entrepreneurs, who account for almost half of all licensees and 40.77% of all licenses for pharmaceutical activities.
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The third parameter that deserves attention is the ratio of urban and rural licensees. In our study, the corresponding number was 3.66 : 1, i.e. 300 licensees operating in urban areas (78.5%) with 436 (79.7%) licenses accounted for 82 (21.5%) rural licensees with 111 (20.3%) licenses.
Thus, an excessive concentration of a pharmaceutical organizational resource, including individual entrepreneurs, most often owners of pharmacies, in cities (79.7% of licensees), is a problem, while almost half of the population of the republic lives in rural areas. This problem significantly reduces the availability of drug care to the rural population of the KBR.
In the process of evaluation of personnel pharmaceutical resource, it was found out that the statistical records of pharmaceutical personnel (pharmaceutists and pharmacists) at the Federal level are conducted only in respect of their training -the number of applicants and the number of graduates. Information on the number of pharmaceutists and pharmacists employed in the drug supply system at the country or regional level could not be identified from available sources.
In this regard, the estimated number of pharmaceutical professionals in Russia as a whole was determined using two different methods: 1) on the basis of extrapolation of official data, as of 1998, and 2) taking into account trends in the development of the pharmacy network of the country and the number of available pharmaceutists and pharmacists ( The foregoing leads to the conclusion about the intensive development of the pharmaceutical human resources in the Russian Federation and the high availability of pharmaceutical personnel to the country's population. At the same time, the lack of official statistical records of pharmaceutical personnel, primarily in the regions, does not allow assessing the analyzed resource properly from the point of view of the actual state, the region's need for such personnel and the satisfaction of this need. The methodical approach used further for the assessment of regional medicinal resource for CAP treatment, provided marketing characteristics of the resource in the qualitative and quantitative (assortment) and price aspects at the following levels:
− lists of drugs for CAP pharmacotherapy, which are the starting point for the assessment of the Russian market for this target segment and, accordingly, − the wholesale pharmaceutical market of the KBR; − the retail pharmaceutical market of the KBR. (3); the total number of the countries producing drugs of this target segment was 39 non-recurring names; -the largest number of dosage forms accounted for tablets was 148 (37.76%); -the number of oral drugs (61.74%) was twice as large as the number of parenteral ones (Table 3) .
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The obtained data were used for comparison with the actual state of the medicinal resource in the KBR, primarily in pharmaceutical wholesale organizations that meet the needs of hospital and retail sectors of the regional market in the target segment medicinal preparations for pneumonia treatment.
The assortment profiles made up for the target drug segment in the federal and regional (wholesale) markets, are presented in Fig. 3 .
As Fig. 3 shows, the regional range is significantly poorer than that in the Russian Federation on the whole -in the number of INNs, the number of trade names and the number of dosage forms. However, in the KBR the proportion of oral drugs and tablets is significantly higher.
The revealed facts make it possible to draw a conclusion about the lack of completeness and breadth of the range of this target segment in the regional pharmaceutical market.
Thus, marketing studies have shown that the development of the regional medicinal resource for the CAP treatment is characterized by satisfying the need for the rangerecommended by the CAP treatment standards, by about 78%, while oral drugs make up about 91%. In the region, there is also a significant differentiation in drugs prices for the CAP treatment.
At the next stage, the internal factors of PhC affecting pharmacotherapy and its consequences for CAP patients were studied. The following factors have been established:
-pharmaceutists and pharmacists of pharmacy organizations are practically not considered by medical specialists as informants and consultants on drug issues. Consequently, the interaction in the process of pharmacotherapy as a mandatory element of PhC is not developed, and a high qualification of pharmaceutical workers is not used by doctors to the proper extent;
ОРИГИНАЛЬНАЯ СТАТЬЯ
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Figure 3 -Assortment profile of funds for pneumonia treatment
-the group of the highest medical trust (preferences) includes only one drug -Moxifloxacin; above the average confidence there is a combination of Ipratropium bromide + Fenoterol, Fluconazole, Acetylcysteine; -according to the survey of pharmacists, the key factors determining a patient's choice when buying a drug for flu and cold treatment, are the price and recommendations of a pharmacists and a pharmaceutists (60% and 43%, respectively); -only a quarter of patients (23%) respond the doctor's recommendations. The data obtained are consistent with the results of an expert survey of doctors: all experts agree that self-treatment exacerbates the course of the disease; -the highest consumer demand is typical of a group of remedies for symptom control (87%); -patients tend to change the prescribed therapy or make up an independent decision when choosing a drug therapy. The revealed differences between pharmacy consumer demand and the preferred prescriptions of medical experts in relation to the required drugs indicates high risks in the self-selection of antibacterial drugs by patients; the consequences of these risks may be the inefficiency of the chosen pharmacotherapy, complications and side effects, increased resistance of microorganisms.
In the study of CAP in-patients, such negative behavioral characteristics of CAP patients as a high tendency to self-treatment and the use of antibiotics without a doctor's prescription were revealed. As a rule, the duration of the use of antibacterial drug is often not familiar to the patient.
These circumstances are consistent with the data obtained in the survey of medical experts and specialists of pharmacy organizations, and serve as an undoubted basis for purposeful informing patients about the properties and risks of the use of antibacterial agents without medical supervision.
Among the most influential factors of pharmacotherapy is the factor of its cost, dependent on the price of a medicinal preparation, so we have analyzed the prices of medicinal preparations under the trade names, registered for INNs, and referred to in the standard of care for pneumonia patients.
It has been established that the minimum differences in price are characteristic of Ampicillin preparations (5.2 rubles), the maximum ones are for Ambroxol (1061.2 rubles), Levofloxacin (1452.2 rubles) and Moxifloxacin (3158.6). The obtained data correspond to the global practice and are the reasons for the emergence of stepwise antibiotic therapy, in which the ways of drug administration are combined. This increases efficiency and reduces the cost of treatment.
Based on these factors, the cost of oral and parenteral antibiotic therapy using the equivalent course dose was compared. It was revealed that the average cost of oral therapy with antibacterial drugs is 917.5 rubles, the cost of parenteral therapy is 5127.7 rubles. The minimum cost of antibiotic therapy is 219.9 rubles (the oral course of Ciprofloxacin), the maximum cost is 13913.4 rubles (parenteral course of Moxifloxacin).
Thus, the cost of a drug therapy course for CAP
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Volume VII, Issue 3, 2019 varies significantly depending on the drug's dosage form and the way of its administration. Based on the generalization of the research results and from the standpoint of the resource approach, a conceptual model for optimizing the drug supply of CAP patients in the KBR has been developed (Fig. 4) . The model consists of two parts:
-results of the assessment of the external factors (resources) of drug supply for CAP patients in Kabardino-Balkaria; -results of the study of the internal factors of CAP pharmacotherapy (physician, patient, pharmaceutical worker; drug supply -the range and price).
Figure 4 -Scheme of conceptual model optimization of drug provision for patients with community-acquired pneumonia in the region
The results of the factors' assessment are considered as problems causing a set of risks for drug provision and pharmacotherapy of CAP. Scientifically grounded organizational and methodological solutions aimed at reducing or eliminating manageable risks (mainly caused by internal factors) have been offered in the study.
The external factors that affect the provision of CAP treatment drugs comprise socio-demographic, organizational, personnel, financial (population) and drug resources. The main problem of these resources within the territory of the KBR is their deficit.
In particular, with regard to the organizational pharmaceutical resource, the notable problems identified in the course of the research, were the lack of accounting of pharmacy organizations and the concentration of pharmacy activities in urban areas.
The risks are: -the difficulty of monitoring and assessing the availability of pharmaceutical organizations to the population of the KBR; -reducing the availability of PhC for rural residents. The possible solutionis are: renewal of the previously existing system of official statistics of pharmaceutical organizations and adjustment of their location. The main problem of the pharmaceutical human resources in the KBR is the lack of official records of pharmaceutical personnel, which leads to such risks as:
1) hiring non-core personnel to work; 2) decline in the quality of pharmaceutical services provided to the population. A possible solution, as in the previous case, is to resume the pre-existing statistics of pharmaceutists and pharmacists.
Insufficiency of the medicinal resource is in the fact that the needs of the region for CAP treatment are only satisfied by 78%. This leads to the risk of reducing the physical accessibility of drugs to the public and medical organizations. A possible solution to the problem is a scientifically based and adequate determination of the region's need for drugs to carry out CAP pharmacotherapy, which, in turn, will require further training of pharmaceutical specialists in this field.
The problem of insufficient financial resources of the Kabardino-Balkarian population is confirmed by the fact that the average per capita income is lower than in the Russian Federation. Accordingly, there is a risk of reducing the economic availability of drugs for CAP patients. The prospect of a successful solution to this problem is uncertain and poorly manageable.
The problems of the socio-demographic resource of the KBR are associated with the following trends: 1) a higher rate of population aging than in the Russian Federation; 2) lower, than in the Russian Federation, share of the average annual number of employees in the total population (impact on per capita incomes); 3) outpacing, in comparison with the Russian Federation, increase in the overall incidence and CAP incidence.
These problems cause the risk of increasing the need for preferential and free drugs, as well as geriatric medical and pharmaceutical care. The possible solutions are: a systematic maintenance of regional registers of Thus, the proposed model shows that the influence of the external factors (resources of the region) leads to the risks associated with a decrease in the physical and economic accessibility of drugs to the population of the KBR as a whole and CAP patients -in particular, against the background of a decrease in the financial security of the citizens living in the region.
The second group of factors involved in the conceptual model is internal, based on the personal, behavioral characteristics of the participants in the pharmacotherapy process and, accordingly, PhC -the team of a physician, a patient and a pharmaceutical worker. In addition to this group of factors, the "behavior" of the drug company is attributed as one of the objects of the pharmaceutical market in the region, in particular, the variability of the cost of the drug itself and its course dose.
The main problem for this group of factors is subjectivity of behavior:
-doctor prescribing a drug for CAP pharmacotherapy, taking into account his qualification, experience, standards of treatment in force, etc.; -patient who does not have sufficient knowledge to properly take the drug in case of pneumonia and even often cannot make the right choice in favor of going to the doctor, not to a pharmacy; -pharmaceutist, more interested in the rapid implementation of the drug, than in the preliminary direction of the patient to hospital for a detailed assessment of the patient's condition. The risks arising from the problem of the subjectivity of the behavior of participants in PhC may, of course, be very high and serious, in terms of aggravating the disease, complications and the development of side effects.
Thus, assessing the risks of internal factors included in the model, it can be argued that all of them (a doctor, a patient and a pharmacist) are closely related to the level of their knowledge about CAP and its pharmacotherapy. Therefore, the most important solution to the subjectivity problem is to increase the level of knowledge of each participant of PhC, as well as timely and complete informe all participants in the pharmacotherapy process about CAP and its pharmacotherapy.
Such organizational and methodological solutions as the study of medical preferences, consumer demands and the opinion of pharmacy specialists regarding drugs used for CAP, have been referred to the elements of such kind of information.
Taking into account a high need of all participants of PhC for information about the CAP disease, its pharmacotherapy and related risks, specific drugs for CAP treatment and their costs in the Kabardino-Balkarian market, a methodological guide has been developed to provide information and consulting services to doctors and patients with CAP in the framework of PhC.
CONCLUSION
Thus, the state and trends of the development of organizational, personnel, socio-demographic, financial (in relation to the population) and drug resource as external factors of the drug supply system of the KBR region have been identified. It has also been established that they are insufficient to fully provide CAP patients with the required drugs.
The main problems of pharmacotherapy of CAP patients, associated with insufficient drug and informational support of doctors and patients, as well as weak interaction between medical and pharmaceutical workers, low awareness of patients about the risks of uncontrolled antibacterial drugs have been determined. In this connection, more intensive development of PhC is needed in the region.
As a result of the comprehensive research, the working hypothesis put forward previously, has been confirmed. Its use makes it possible to form a dynamic conceptual model of improving drug supply and pharmacotherapy of patients with CAP at the regional level by monitoring external and internal factors and determining the factors that are amenable to directional managerial influences.
